Posted by Michael Wonder on 11 Feb 2025
Bayer files for approval of extended 6 month treatment interval for Eylea 8 mg in the EU
10 February 2025 - Bayer submitted an application to the EMA to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/mL solution for injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema.
The submission is based on positive three year results from the open-label extension studies of the clinical trials PULSAR (in age related macular degeneration) and PHOTON (in diabetic macular oedema).
